Johnson & Johnson posts press release on MonumenTAL-6 multiple myeloma trial results

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • Johnson & Johnson posted a July 23, 2026 press release on Phase 3 MonumenTAL-6 results in relapsed/refractory multiple myeloma.
  • TECVAYLI + TALVEY cut risk of disease progression or death by 89% (HR 0.11), risk of death by 62% (HR 0.38).
  • TALVEY + pomalidomide reduced risk of progression or death by 73% (HR 0.27) versus standard of care.
  • IDMC recommended unblinding at the first interim analysis; results to be presented at a future medical meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230830PR_NEWS_USPR_____NY09774) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.